Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Beta Bionics, Inc.NASDAQ: BBNX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 28.9% from a year ago
Cash & equivalents stood at $30.21M at the end of Q1 FY2026, down 28.9% from a year earlier and down 4.3% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.
Context
- Cash & equivalents amounted to 9.9% of total assets at the end of Q1 FY2026, down 2.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -28.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 31.58M USD
- Year-over-year change
- +3.8%
- 3-year CAGR
- +4.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.58M | +3.8% |
| FY2024 | 2024-12-31 | 30.43M | +14.6% |
| FY2023 | 2023-12-31 | 26.57M | -4.0% |
| FY2022 | 2022-12-31 | 27.68M | — |
Cash & Equivalents vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -28.9% is the 5th highest of 7, against a peer median of +3.5%.
- Cash & equivalents amounts to 9.9% of total assets for BBNX, versus a peer median of 7.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 44.48B DKK | +141.3% | +27.9% | 7.5% | |
| Jun 2026 | $1.11B USD | -4.7% | +12.6% | 17.1% | |
| Jun 2026 | $534.9M USD | -46.1% | +4.7% | 16.9% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $207M USD | — | — | 4.4% |
| Mar 2026 | $179.33M USD | +234.7% | -19.3% | 15.5% | |
| Mar 2026 | $52.83M USD | +11.7% | +2.4% | 7.1% | |
| Mar 2026 | $30.21M USD | -28.9% | +4.5% | 9.9% | |
| Mar 2026 | $13.2M USD | -82.3% | +4.3% | 4.9% | |
| Peer median (excluding BBNX) | — | +3.5% | +4.5% | 7.5% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.